Alma vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health network connecting clients to in-network therapists; handles credentialing, billing, and insurance contracting for affiliated clinicians; one of largest US therapist networks.
About
Alma is a New York-based mental health company that operates a network of therapists and psychiatrists, providing them with the business infrastructure to run private practices while accepting insurance. Alma handles credentialing, billing, insurance contracting, and administrative tasks for affiliated clinicians, enabling therapists to focus on patient care rather than paperwork while earning more than they could through employment at a group practice. On the patient side, Alma makes it easier to find available in-network therapists — a persistent challenge in mental healthcare — through its searchable directory of affiliated providers across the country. Alma has built one of the largest networks of private practice therapists accepting insurance in the United States, with thousands of clinicians across most states. Founded in 2017, Alma raised over $220M from investors including Insight Partners, Tiger Global, and Optum Ventures. The company addresses both sides of the mental health access crisis: insufficient supply of providers and inadequate insurance reimbursement making private practice financially unviable.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.